bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic.

Abstract

In an unblinded trial in 452 patients with persistent, recurrent or metastatic cervical cancer, adding bevacizumab to other cytotoxic drugs prolonged median survival by 4 months, but adverse effects were often severe and sometimes fatal. Tailored symptomatic care is also a valid option.